|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12345678910111213...1314» |
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 18, 2017
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Dec 2017 N=200 --> 41
- | Enrollment closed: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Apr 11, 2017
P2, N=9, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=200 --> 41 Recruiting --> Active, not recruiting
- | Trial completion: Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=5, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 31, 2017
P2, N=74, Completed, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=17, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 17 | Trial primary completion date: Dec 2016 --> Feb 2012
- | Rituxan (rituximab) / Roche
Enrollment change, Trial primary completion date: RBL: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=43, Completed, Sponsor: Gachon University Gil Medical Center
Active, not recruiting --> Completed | N=100 --> 17 | Trial primary completion date: Dec 2016 --> Feb 2012 N=55 --> 43 | Trial primary completion date: May 2013 --> Mar 2014
- Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Feb 23, 2017
P1, N=44, Active, not recruiting, Sponsor: Craig Hofmeister
N=55 --> 43 | Trial primary completion date: May 2013 --> Mar 2014 Trial primary completion date: Oct 2014 --> Jan 2017
- | Enrollment closed, Trial primary completion date: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: Vanderbilt University Medical Center
Trial primary completion date: Oct 2014 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Feb 14, 2017
P2, N=0, Withdrawn, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014 N=67 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Jan 2017
- OXS-1550 / GT Biopharma
Trial completion, Trial initiation date: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1, N=25, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=67 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013
- Trial termination: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Terminated, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013 Active, not recruiting --> Terminated; slow accrual
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment closed: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Baylor College of Medicine
Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 17, 2017
P2, N=71, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 12, 2017
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Oct 2015
- melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Trial completion: Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 10, 2017
P2, N=37, Completed, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Dec 2016 --> Oct 2015 Active, not recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Trial completion: Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 14, 2016
P1, N=20, Completed, Sponsor: Yale University
Active, not recruiting --> Completed No longer recruiting --> Completed
- Trial primary completion date: Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer (clinicaltrials.gov) - Dec 8, 2016
P3, N=472, Completed, Sponsor: Radiation Therapy Oncology Group
No longer recruiting --> Completed Trial primary completion date: Oct 2008 --> Mar 2005
- | Trial completion: Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer (clinicaltrials.gov) - Dec 7, 2016
P3, N=472, Completed, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Oct 2008 --> Mar 2005 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 7, 2016
P2, N=58, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Feb 2008 --> Jul 2003
- Enrollment closed, Trial primary completion date: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Nov 18, 2016
P1, N=16, Active, not recruiting, Sponsor: Robert Lowsky
Trial primary completion date: Feb 2008 --> Jul 2003 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2016
- | alisertib (MLN8237) / Puma
Trial completion: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (clinicaltrials.gov) - Nov 14, 2016
P1/2, N=43, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2016 Active, not recruiting --> Completed
- Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 9, 2016
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Sep 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
Trial termination, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 2, 2016
P1, N=1, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Mar 2017 --> Sep 2017 Active, not recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Feb 2015; Slow Accruals
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Oct 18, 2016
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Feb 2015; Slow Accruals Trial primary completion date: Jan 2015 --> Apr 2017
- Yervoy (ipilimumab) / BMS
Phase classification: Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (clinicaltrials.gov) - Sep 26, 2016
P1, N=89, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Jan 2015 --> Apr 2017 Phase classification: P2 --> P1
- | Yervoy (ipilimumab) / BMS
Trial completion: Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (clinicaltrials.gov) - Sep 25, 2016
P1, N=89, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Phase classification: P2 --> P1 Recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 21, 2016
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Completed Trial primary completion date: Jun 2016 --> Jan 2015
- melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Trial primary completion date: Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 21, 2016
P2, N=37, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jun 2016 --> Jan 2015 Trial primary completion date: Jan 2014 --> Aug 2015
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Sep 21, 2016
P1/2, N=204, Completed, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 15, 2016
P1, N=1, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016
- Istodax (romidepsin) / Astellas, BMS, Rituxan (rituximab) / Roche
Enrollment change, Trial initiation date, Trial withdrawal: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2016
P1/2, N=0, Withdrawn, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016 N=56 --> 0 | Initiation date: Jun 2016 --> Oct 2016 | Not yet recruiting --> Withdrawn
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 28, 2016
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
N=56 --> 0 | Initiation date: Jun 2016 --> Oct 2016 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Jun 2017
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
Trial primary completion date: Dec 2015 --> Jun 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients With Solid Tumors (clinicaltrials.gov) - Jul 16, 2016
P3, N=365, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jul 14, 2016
P2, N=0, Withdrawn, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed N=38 --> 0 | Suspended --> Withdrawn
- | topotecan / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 12, 2016
P2, N=0, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=38 --> 0 | Suspended --> Withdrawn No longer recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 11, 2016
P3, N=344, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Metastases: Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss (clinicaltrials.gov) - Jul 11, 2016
P1/2, N=63, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed No longer recruiting --> Completed
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 3, 2016
P2, N=134, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=82, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jun 22, 2016
P1, N=38, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Jun 16, 2016
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Jul 2017
- Enrollment change, Trial withdrawal: Treg Cells for AGVHD in Non-myeloablative UCB Transplant (clinicaltrials.gov) - Jun 15, 2016
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Mar 2016 --> Jul 2017 N=18 --> 0 | Not yet recruiting --> Withdrawn
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 8, 2016
P1, N=25, Completed, Sponsor: Regeneron Pharmaceuticals
N=18 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 8, 2016
P1, N=25, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion: VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 8, 2016
P1, N=0, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Biomarker, Trial completion, Trial primary completion date: AALL12B3: Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=70, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Sep 2016 --> Mar 2017